Cargando…

Use of Antifungals and Outcomes Among Inpatients at Risk of Invasive Aspergillosis or Mucormycosis in the USA: A Retrospective Cohort Study

INTRODUCTION: Prophylaxis and treatment of invasive aspergillosis (IA) and mucormycosis (IM) within a real-world US inpatient setting is undocumented since the introduction of isavuconazole. This retrospective medical record review aimed to describe characteristics, triazole use, and outcomes among...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stull, Katherine, Esterberg, Elizabeth, Ajmera, Mayank, Candrilli, Sean, Kitt, Therese M., Spalding, James R., Patel, Vanessa Perez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856226/ https://www.ncbi.nlm.nih.gov/pubmed/31598932 http://dx.doi.org/10.1007/s40121-019-00267-4

Ejemplares similares

Impact of antiepileptic-drug treatment burden on health-care-resource utilization and costs
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

Recent Trends in Hypoparathyroidism-Related Inpatient and Emergency Department Admissions and Costs in the United States
por: Kaul, Sanjiv, et al.
Publicado: (2023)

Nanomaterial-Based Antifungal Therapies to Combat Fungal Diseases Aspergillosis, Coccidioidomycosis, Mucormycosis, and Candidiasis
por: León-Buitimea, Angel, et al.
Publicado: (2021)

Advances against Aspergillosis and Mucormycosis
por: Stevens, David A.
Publicado: (2020)

Invasive pulmonary mucormycosis and aspergillosis in a patient with decompensated hepatic cirrhosis
por: Persichino, Jon G., et al.
Publicado: (2018)

Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations
por: Egger, Matthias, et al.
Publicado: (2023)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

Comparison of Clinical Manifestation, Diagnosis, and Outcomes of Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis
por: Lin, Chun-Yu, et al.
Publicado: (2019)

The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19
por: Ghosh, Asmita, et al.
Publicado: (2021)

P407 Standardization of PCR for the diagnosis of invasive aspergillosis and invasive mucormycosis from blood samples
por: Rompally, Satwika, et al.
Publicado: (2022)

1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
por: Arrieta, Antonio C, et al.
Publicado: (2023)

Oral Mucormycosis and Aspergillosis in the Patient with Acute Leukemia
por: Vučićević Boras, Vanja, et al.
Publicado: (2019)

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
por: Banck, Jan Christoph, et al.
Publicado: (2021)

COVID-19 associated with concomitant mucormycosis and aspergillosis
por: Lai, Chih-Cheng, et al.
Publicado: (2022)

Dexamethasone: Pulmonary aspergillosis and mucormycosis: case report
Publicado: (2021)

Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?
por: Walsh, Thomas J., et al.
Publicado: (2020)

Immunosuppressants/Antifungals: COVID-19 associated mucormycosis, COVID-19 associated pulmonary aspergillosis and lack of efficacy: case report
Publicado: (2022)

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations
por: Natesan, Suganthini Krishnan, et al.
Publicado: (2016)

Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management
por: Rudramurthy, Shivaprakash M., et al.
Publicado: (2019)

TREM1 regulates antifungal immune responses in invasive pulmonary aspergillosis
por: Bernal-Martínez, L, et al.
Publicado: (2021)

Pulmonary aspergillosis and mucormycosis in a patient with COVID-19
por: Johnson, Andre K., et al.
Publicado: (2021)

Isolated cerebral Mucormycosis and Aspergillosis coinfection in an immunocompromised adult
por: Sun, George, et al.
Publicado: (2023)

Post-COVID-19 Gastrointestinal Invasive Mucormycosis
por: Jain, Mayank, et al.
Publicado: (2021)

Molecular Mechanisms of Antifungal Resistance in Mucormycosis
por: Ganesan, Priya, et al.
Publicado: (2022)

Management of mucormycosis coexisting with aspergillosis in pediatric age group – a case report
por: Gopal, Ashish, et al.
Publicado: (2023)

Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature
por: Mayr, A, et al.
Publicado: (2011)

Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis
por: Lee, Dong‐Gun, et al.
Publicado: (2019)

Mucormycosis and Aspergillosis Infection Following Maxillofacial Trauma: Case Report
por: Sardeshmukh, Amruta Anil, et al.
Publicado: (2023)

Coinfection pulmonary mucormycosis and aspergillosis with disseminated mucormycosis involving gastrointestinalin in an acute B-lymphoblastic leukemia patient
por: Hu, Zhi-min, et al.
Publicado: (2021)

Comparison of serum PCR assay and histopathology for the diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients with sinus involvement
por: Shokouhi, S, et al.
Publicado: (2016)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2021)

745. Combination Treatment of Liposomal Amphotericin B and Isavuconazole is Synergistic in Treating Experimental Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
por: Borroto-Esoda, Katyna, et al.
Publicado: (2017)

Potential antifungal targets based on histones post-translational modifications against invasive aspergillosis
por: Li, Yiman, et al.
Publicado: (2022)

GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive Aspergillosis
por: Shaw, Karen Joy
Publicado: (2022)

Molecular epidemiology and antifungal susceptibilities of Aspergillus species isolated from patients with invasive aspergillosis
por: Sarigüzel, Fatma Mutlu, et al.
Publicado: (2023)

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients
por: Tissot, Frederic, et al.
Publicado: (2017)

Fatal Mucormycosis and Aspergillosis in an Atypical Host: What Do We Know about Mixed Invasive Mold Infections?
por: Tsikala-Vafea, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mpj9j03u4j08d7u0e2vsu56qge